Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07490262CT.gov A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. | — | Recruiting | — | — | — |
NCT07392866CT.gov A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07328009CT.gov A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07309419CT.gov A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT06349044CT.gov A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies. | — | Recruiting | — | — | — |
NCT05976568CT.gov A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT06818097CT.gov Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC | — | Completed | — | — | — |
NCT05007106CT.gov MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | — | Completed | — | — | — |
NCT04411706CT.gov A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03744247CT.gov Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC | — | Withdrawn | — | — | — |
Show 21 more trialsShow fewer
NCT03914352CT.gov A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection | — | Unknown | — | — | — |
NCT03780634CT.gov HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC | — | Withdrawn | — | — | — |
NCT03803254CT.gov HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC | — | Withdrawn | — | — | — |
NCT03791918CT.gov Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria | — | Withdrawn | — | — | — |
NCT03746249CT.gov Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC | — | Withdrawn | — | — | — |
NCT03782831CT.gov TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC | — | Withdrawn | — | — | — |
NCT03775707CT.gov Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria | — | Withdrawn | — | — | — |
NCT03563170CT.gov QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | — | Withdrawn | — | — | — |
NCT03114085CT.gov Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03578874CT.gov SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC | — | Completed | — | — | — |
NCT02716766CT.gov Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT02423343CT.gov A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02288507CT.gov Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer | — | Withdrawn | — | — | — |
NCT01245582CT.gov Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients | — | Withdrawn | — | — | — |
NCT01061515CT.gov Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT01032850CT.gov Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT00752063CT.gov Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT00464295CT.gov Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC) | — | Completed | — | — | — |
NCT02576964CT.gov A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer | — | Completed | — | — | — |
NCT00076609CT.gov Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00635323CT.gov Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capecitabine (this asset) | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | P3 | B · 60 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Capecitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Carcinoma | — | P4 | BBB · 73 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Capecitabine in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/capecitabine-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →